News

Chemomab Presents Promising Nebokitug Data at BSG Live’25

Chemomab Presents Promising Nebokitug Data at BSG Live’25

Chemomab Showcases Promising Results for Nebokitug at BSG Live’25

At the recent BSG Live’25 conference, Chemomab Therapeutics, Ltd. (NASDAQ: CMMB) unveiled exciting data from its Phase 2 SPRING trial concerning nebokitug, a novel treatment targeting primary sclerosing cholangitis (PSC). This oral presentation highlighted the robust clinical potential of nebokitug, leading discussions on its advancement to the Phase 3 trial stage.

Results of the SPRING Trial

Presented by Dr. Douglas Thorburn, this vital trial showcases nebokitug's ability to provide significant health benefits for PSC patients. The data indicates that the treatment is both safe and well-tolerated over a 48-week period, notably improving multiple fibrotic and inflammatory biomarkers. These factors are indicative of slowing the progression of the PSC disease, a progressive and often life-threatening liver condition.

A Positive Outlook for PSC Treatment

Dr. Thorburn emphasized that PSC has long been a challenging condition to treat, with few effective therapies available. The data from the SPRING trial's double-blind, placebo-controlled portion revealed that patients receiving nebokitug displayed significant, dose-dependent improvements in anti-inflammatory and anti-fibrotic effects. Patients with more active forms of the disease specifically saw promising advancements in their overall health.

Prolonged Benefits with Additional Treatment

Furthermore, the presentation covered findings from the trial’s open-label extension, where all eligible patients continued their treatment. Notably, these participants received nebokitug for up to an additional 33 weeks after the initial phase. Results showed that the treatment remains safe and well-tolerated throughout this extended duration, providing sustained beneficial effects for patients battling PSC.

Comments from Chemomab's Leadership

Adi Mor, PhD, the CEO and co-founder of Chemomab, expressed excitement over the trial’s implications, particularly the significance of presenting at such a distinguished gathering. He acknowledged the critical need for new therapies to address the challenges PSC patients face daily. As the company gears up for a Phase 3 trial, there is optimism that nebokitug could soon lead the way as the first approved therapy for PSC.

Understanding Nebokitug and Its Development

Chemomab is at the forefront of expanding treatment options for fibrotic diseases. Nebokitug (CM-101), a pioneering monoclonal antibody, works by neutralizing the soluble protein CCL24, which has a known role in promoting fibrosis and inflammation. Its successful Phase 2 results are a testament to its potential. With positive data from four previous clinical trials under its belt, Chemomab is poised for significant advancements in the field of hepatology.

Future Directions

The design of the upcoming Phase 3 trial emphasizes a streamlined approval pathway focused on primary clinical endpoints. This significant step, combined with its Orphan Drug and Fast Track designations from the FDA, places nebokitug in a favorable position to address unmet needs in PSC treatment. As Chemomab progresses forward, the attention remains on transforming the landscape of care for patients suffering from this challenging condition.

Frequently Asked Questions

What is nebokitug?

Nebokitug (CM-101) is a dual activity monoclonal antibody developed by Chemomab that targets CCL24, showing promise in treating conditions like primary sclerosing cholangitis.

What were the key findings from the SPRING trial?

The SPRING trial data indicated that nebokitug is safe and well-tolerated, demonstrating significant improvement in biomarkers linked to PSC progression over a treatment period of 48 weeks.

Who presented the SPRING trial results?

Dr. Douglas Thorburn presented the SPRING trial results at the BSG Live’25 conference, highlighting the benefits of nebokitug for patients with primary sclerosing cholangitis.

What is the significance of the Phase 3 trial for nebokitug?

The Phase 3 trial is crucial as it seeks to establish a clear pathway for nebokitug to gain regulatory approval as the first effective therapy for PSC.

What does the future hold for Chemomab and nebokitug?

Chemomab aims to initiate the Phase 3 trial soon, building on encouraging data and striving to be a leader in the treatment of fibro-inflammatory conditions like PSC.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

IAS Marks 42 Years Amid Germany Religious Freedom Win

Updated Category News Views 13

Bagpipes, country roads and a gathering from six continents made this far more than a routine anniversary reception. The International Association of Scientologists marked its 42nd anniversary at Saint Hill in East Grinstead, England, with thousands of Scientologists and guests arriving as autumn settled over West Sussex. That sort of turnout is a visible statement of...

Continue Reading
Rafay's Third Fast 500 Nod Tracks AI Cloud Buildout

Updated Category News Views 67

GPU warehouses are easy to admire and brutally hard to operate like a real business. Rafay Systems landing on Deloitte's 2026 Technology Fast 500 for a third straight year is another signal that the AI infrastructure scramble has moved well beyond simply finding chips. Somebody has to turn all that expensive compute into services customers can provision, use, measure and...

Continue Reading
Stanford Forum Puts Industrial AI in the Real World

Updated Category News Views 136

Factory Data Is Not a Free Lunch A factory dataset is worth precisely nothing if its owner cannot control it. That was the hard-nosed thread running through the ASI City Forum at Stanford on November 17: industrial AI is not just about smarter models or splashy chip announcements. It is about whether manufacturers will trust a system with proprietary operating data,...

Continue Reading
MetaComp's $10M Extension Tests Stablecoin Rails in Trade

Updated Category News Views 78

A ten-million-dollar check is cheap until the licensing bills start arriving. MetaComp has added roughly US$10 million from Tether and Abu Dhabi-based Further Asset Management, taking its Pre-A and Pre-A+ fundraising to about US$45 million. The important bit is not the headline-sized pile of cash. It is where management says the money is going: licences, compliance...

Continue Reading
Ajman Forum Puts Trust at the Center of Crisis Media

Updated Category News Views 63

Rumours do not wait politely for a communications team to finish its meeting. That plain reality sat underneath Abdulla bin Mohammed bin Butti Al Hamed's keynote at Ajman Media Forum 2026, and it is a tougher point than the usual talk about reach, engagement, or flashy new technology. In a crisis, an information vacuum gets filled fast, usually by somebody with no...

Continue Reading
RMT’s 12.4% Discount Still Demands a Much Harder Look

Updated Category News Views 58

A $1.84 gap is staring RMT shareholders right in the face. As of October 31, 2026, Royce Micro-Cap Trust carried a net asset value of $14.82 per share while the market price sat at $12.98. That is roughly a 12.4% discount to NAV, and closed-end fund investors should never wave off a spread like that with a lazy shrug. It may be opportunity. It may also be the market...

Continue Reading
IQSTEL’s 2027 Plan Has Scale but Still Needs Proof

Updated Category News Views 46

A $313 million nine-month revenue figure gets attention, yet this story is really about whether IQSTEL can finally turn a big telecom pipe into money that sticks. The company grew consolidated revenue 34.5% year over year through September 30, 2026, and third-quarter revenue hit $106.0 million, its second straight quarter above $100 million. That is real operating scale,...

Continue Reading
Qiandaohu Whisky Film Puts Craft Before Market Hype

Updated Category News Views 59

Three Distillers, One Very Large Question Whisky does not become world-class because a camera crew found a pretty shoreline. That is the blunt truth sitting underneath this Nov. 19, 2026 documentary release from CCTV+. The film follows three international distillers working at three separate whisky distilleries along Qiandaohu, while also lingering on their day-to-day...

Continue Reading
Pennsylvania Rebate Rules Matter Before Year-End Filing

Updated Category News Views 80

A missed rebate form can sting harder than most people expect, especially when a household has already spent the year watching property taxes, rent, groceries, and every other stubborn bill chew through fixed income. Pennsylvania’s Property Tax/Rent Rebate Program is not glamorous, and it is certainly not an investing story. It is, however, the kind of direct household...

Continue Reading
Vision Marine's Cash Cleanup Meets a Hard Reality Ahead

Updated Category News Views 117

A boat dealer slashing debt by $27.5 million deserves a nod, even when the rest of the ledger still makes your eyebrows climb. Vision Marine Technologies turned fiscal 2026 into a working-capital cleanup job: inventory came down hard, floor-plan financing nearly vanished, and operating cash flow finally turned positive. For NASDAQ:VMAR, that is real progress. It is not,...

Continue Reading

Top 5 Most Recently Viewed Articles

Global Technology Acquisition Corp. I Initiates Liquidation Process

Updated Category News Views 212

Global Technology Acquisition Corp. I Announces Dissolution of Operations Global Technology Acquisition Corp. I (Nasdaq: GTAC) finds itself at a pivotal moment, as the company has declared its intent to dissolve and liquidate its operations. This decision arises from the inability to complete an initial business combination within the mandated timeframe outlined in its...

Continue Reading
Empowering Leadership Development: McLean & Company Insights

Updated Category News Views 483

Leadership Development: Key to Organizational Success In today's fast-evolving work landscape, the significance of leadership development has never been clearer. Global HR research firm McLean & Company emphasizes that cultivating effective leaders at every level is crucial for organizational success. Their comprehensive research highlights a four-step process that...

Continue Reading
Investigation Launched into Aviat Networks, Inc. Securities Fraud

Updated Category News Views 144

Investigation into Aviat Networks, Inc. Recent developments regarding Aviat Networks, Inc. have raised significant concerns among investors about their financial future. The company is now under scrutiny from legal experts due to possible allegations of securities fraud. The Portnoy Law Firm is actively investigating these issues and has begun reaching out to investors...

Continue Reading
GR Silver Mining Plans $1.76 Million Private Placement Funding

Updated Category News Views 99

GR Silver Mining Ltd.'s Strategic Private Placement GR Silver Mining Ltd. (GRSL, GRSLF) has announced a plan to raise up to $1.76 million through a non-brokered private placement. This strategic initiative is designed to boost exploration efforts, particularly focusing on expanding resources at the San Marcial Area within the Plomosas Project. Details of the Offering The...

Continue Reading
BRT Apartments Corp. Declares Exciting New Dividend

Updated Category News Views 121

BRT Apartments Corp. announces a quarterly dividend BRT Apartments Corp. has declared a quarterly dividend of $0.25 per share. Approved by the Board of Directors, this action continues the company’s practice of returning cash to shareholders as part of its ongoing financial plan. It’s a straightforward move that underscores a focus on steady, shareholder-minded...

Continue Reading